Current Research Studies
A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
OMS721-HCT-002 Narsopliamb
What is the goal of the study?
The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of narsoplimab in paediatric-aged patients with thrombotic microangiopathies (TMA) following haematopoietic stem cell transplant (HSCT).
Who can participate in the study?
Please contact the study team listed below to learn more.